UBS Initiates Coverage of HeartFlow at Neutral
Fintel reports that on September 9, 2026, UBS initiated coverage of HeartFlow (NASDAQGS:HTFL) with a Neutral recommendation.
Prior to this rating action, the stock closed at $47.75 on September 8, 2026. This latest close represents a price change of -5.31% over one week, compared to a baseline close of $50.43 on September 1, 2026. Over a longer timeframe, the stock experienced a price change of +65.68% over one month, relative to a baseline close of $28.82 on August 7, 2026.
HeartFlow recently reported its latest earnings on August 13, 2026. The company posted an actual EPS of -0.07, which compared to an estimated EPS of -0.1364. The actual revenue for the period was $64,082,000,000,000.00, exceeding the estimated revenue of $57,775,350,000,000.00.
Separately from UBS's initiation, the current consensus target mean for the stock was recorded at $44.15 as of August 28, 2026, with a median target of $45.90. This mean target represents an implied change of -7.54% from the pre-action close. This is an increase from the prior consensus target mean of $37.59 recorded on August 4, 2026, representing a consensus target revision of +17.44%.
As of the current recommendation period on September 1, 2026, the aggregate analyst sentiment consisted of 5 strong buy, 8 buy, 2 hold, 0 sell, and 0 strong sell recommendations, totaling 15 recommendations. This breakdown reflects 86.7% positive, 13.3% hold, and 0.0% negative recommendations. These figures remained unchanged from the prior recommendation period on August 1, 2026, which also had 15 total recommendations with the same distribution.
Following the company's earnings release, several other analyst firms updated their coverage on August 14, 2026. JP Morgan maintained its Overweight rating, Piper Sandler reiterated its Overweight rating, and Wells Fargo maintained its Overweight rating. Additionally, Canaccord Genuity and Stifel both maintained their Buy ratings, while Morgan Stanley maintained its Equal-Weight rating.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 9, 2026 | UBS | Neutral | initiated coverage | |
| August 14, 2026 | JP Morgan | Overweight | Overweight | maintained |
| August 14, 2026 | Piper Sandler | Overweight | Overweight | reiterated |
| August 14, 2026 | Wells Fargo | Overweight | Overweight | maintained |
| August 14, 2026 | Canaccord Genuity | Buy | Buy | maintained |
| August 14, 2026 | Stifel | Buy | Buy | maintained |
| August 14, 2026 | Morgan Stanley | Equal-Weight | Equal-Weight | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.